Vyriad Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- Vyriad's estimated annual revenue is currently $5.7M per year.
- Vyriad's estimated revenue per employee is $155,000
- Vyriad's total funding is $33.4M.
- Vyriad has 37 Employees.
- Vyriad grew their employee count by 54% last year.
- Vyriad currently has 1 job openings.
What Is Vyriad?
At Vyriad, we are developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. We believe our oncolytic viruses have tremendous potential to improve the lives of patients, inspire hope and change the way cancer is treated.\n\nOur goal is to develop effective viral-based therapies for patients, especially those with significant unmet needs. We are testing our oncolytic viruses as monotherapies or in combination with immuno-oncology drugs. Phase 1-2 clinical studies are under way in non-small cell lung cancer, squamous cell carcinoma of the head and neck, metastatic colorectal cancer, bladder and other types of cancer. A Phase 2 trial in several additional forms of cancers is expected to begin enrolling patients by early 2020. Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, Merck KGaA/Pfizer and other leading research and medical institutionskeywords:N/A